Oncolytics Biotech’s (ONCY) “Buy” Rating Reaffirmed at HC Wainwright

Oncolytics Biotech (NASDAQ:ONCY)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $5.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 385.44% from the stock’s current price.

Oncolytics Biotech Stock Performance

Shares of ONCY opened at $1.03 on Thursday. Oncolytics Biotech has a 52 week low of $0.84 and a 52 week high of $1.75. The firm has a market cap of $79.38 million, a P/E ratio of -3.81 and a beta of 1.69. The firm’s 50-day simple moving average is $1.08 and its 200 day simple moving average is $1.06.

Institutional Investors Weigh In On Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC acquired a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 0.07% of Oncolytics Biotech as of its most recent SEC filing. Hedge funds and other institutional investors own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.